Cephalexin
FDA-approved product (capsule, oral), marketed as Cephalexin, Keflet, Keflex and 2 more.
- Registered studies
- 50+
- Lab records
- 9
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
- Otitis media
- Prostatitis
- Respiratory tract infectious disorder
- Sprain
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- First-generation cephalosporins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DB01
Repurposing investigation
Cephalexin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA97.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli84.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae84.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 4 of 7 lab records
- E. coli: measured active in 1 of 1 lab record
- K. pneumoniae: measured active in 1 of 1 lab record
Show the 9 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cephalexin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more44.6% AI-predicted activityagainst K. pneumoniae16 registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection44.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more44.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more44.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more44.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Baloxavir MarboxilExisting use: Influenza, Viral disease44.0% AI-predicted activityagainst K. pneumoniae24 registered studies
- RivaroxabanExisting use: Acute coronary syndrome, Atrial fibrillation, Coronary artery disease and 9 more43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more43.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more43.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more43.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
NCT01073540 · start 2009-09
Registered record
- Registry ID
- NCT01073540
- Conditions
- Anti-Infective Agents
- Interventions
- Cephalexin suspension (Optocef, BAYO5448); Cephalexin suspension (Keflex)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2009-09
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti-Infective AgentsInterventionCephalexin suspension (Optocef, BAYO5448); Cephalexin suspension (Keflex)PhasePhase 1Registry statusCompletedMoxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
NCT00895089 · start 2009-05
Registered record
- Registry ID
- NCT00895089
- Conditions
- Liver Abscess
- Interventions
- Moxifloxacin (Avelox); ceftriaxone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-05
- Completion
- 2011-12
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLiver AbscessInterventionMoxifloxacin (Avelox); ceftriaxonePhasePhase 4Registry statusCompletedPlacebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
NCT00187759 · start 2004-11
Registered record
- Registry ID
- NCT00187759
- Conditions
- Soft Tissue Infections
- Interventions
- cephalexin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-11
- Completion
- 2005-03
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSoft Tissue InfectionsInterventioncephalexinPhaseNot applicableRegistry statusCompletedCefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.
NCT00835081 · start 2004-09
Registered record
- Registry ID
- NCT00835081
- Conditions
- Healthy
- Interventions
- Cefadroxil 500 mg Capsules; DURICEF® capsules 500 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2004-10
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCefadroxil 500 mg Capsules; DURICEF® capsules 500 mgPhasePhase 1Registry statusCompletedS9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
NCT00003824 · start 1999-04
Registered record
- Registry ID
- NCT00003824
- Conditions
- Bladder Cancer
- Interventions
- cephalexin; surgical procedure; Ciprofloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 1999-04
- Completion
- 2007-01
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBladder CancerInterventioncephalexin; surgical procedure; CiprofloxacinPhasePhase 3Registry statusTerminated